|
|
| |||||||||||||||||||||||||||||||||||||
Many drugs have been found to be highly effective in the primary or secondary prevention of cardiovascular disease. These include aspirin, angiotensin-converting–enzyme (ACE) inhibitors, statins, beta-blockers, and calcium-channel blockers. Despite their potential for saving lives by effectively reducing cardiovascular risk, these drugs have not been used optimally even in developed countries. Poor adherence to multidrug regimens is a common barrier to effective therapy. In low-income and middle-income countries, the unaffordable cost of such regimens represents another obstacle.
Recently, as a way of overcoming these barriers, some observers have been advocating the concept of a "polypill" — a single pill that would include a number of key drugs. Wald and Law have proposed that the combination pill consist of aspirin, an ACE inhibitor, a beta-blocker, a statin, a diuretic, and folic acid.2 Since there is no trial evidence to suggest a benefit from the addition of folic acid or a diuretic to a regimen for preventing coronary disease that already includes two blood-pressure–lowering drugs, others have suggested combinations of four to five drugs that may be customized separately for primary prevention of cardiovascular disease, secondary prevention of coronary heart disease, and secondary prevention of stroke. Recent trial evidence has been cited in support of the recommendation that primary prevention regimens should include a calcium-channel blocker, whereas secondary prevention regimens must include a beta-blocker.3 Aspirin, an ACE inhibitor, and a statin would be incorporated into both types of regimens.
The availability of most of these drugs in a generic form may help to reduce the cost of a polypill, especially in countries such as India, with its active generic drug industry. Moreover, modeled economic analyses suggest that such multidrug regimens would be quite cost-effective in reducing the burden of cardiovascular disease even in low-income and middle-income countries.3 Since current treatment guidelines recommend multiple drugs for the secondary prevention of cardiovascular disease, a polypill would probably be easily accepted for that indication. In the area of primary prevention, however, the value of such a pill would have to be clearly demonstrated, rather than simply assumed.
The World Heart Federation recently announced that it would support the development and evaluation of a polypill consisting of aspirin, an ACE inhibitor, and a statin. Two Indian drug manufacturers have already developed four-drug combination pills (the fourth drug being a beta-blocker) and will soon begin clinical trials. Such trials will provide further information on the cost-effectiveness, safety, and adherence profile of a combination pill and should reveal whether the polypill is a miracle or a mirage. Without such evidence, advocacy for the polypill would be a mere leap of faith.
Source Information
Dr. Reddy is the president of the Public Health Foundation of India and a professor of cardiology at the All India Institute of Medical Sciences, New Delhi.
An interview with Dr. Reddy can be heard at www.nejm.org.
References
| |||||||||||||||||||||||||||||||||||||
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
Interview
